Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model

about

Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.

P2860

Q35662929-F98792F2-2AFB-458F-8E31-63FD00D5E227

P2860

Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model

Item

http://www.wikidata.org/entity/Q36996565

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Cost-utility analysis for plat ...... n/carboplatin sequencing model

@en

type

Item

label

Cost-utility analysis for plat ...... n/carboplatin sequencing model

@en

prefLabel

Cost-utility analysis for plat ...... n/carboplatin sequencing model

@en

P1476

Cost-utility analysis for plat ...... n/carboplatin sequencing model

@en

P2093

Bong-Min Yang

http://www.w3.org/2001/XMLSchema#string

Byoung-Gie Kim

http://www.w3.org/2001/XMLSchema#string

Hwa-Young Lee

http://www.w3.org/2001/XMLSchema#string

Ji-Min Hong

http://www.w3.org/2001/XMLSchema#string

Tae-Jin Lee

http://www.w3.org/2001/XMLSchema#string

Yong-Man Kim

http://www.w3.org/2001/XMLSchema#string

Young-Tae Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Quality of life as a primary end point in oncology.

Epidemiological characteristics of ovarian cancer in Korea.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain.

Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment.

Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.

P304

297-307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CEOR.S42170

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sokbom Kang

Jae-Weon Kim

P577

2013-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23869171

http://www.w3.org/2001/XMLSchema#string

P932

3706255

http://www.w3.org/2001/XMLSchema#string

Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model

about

P2860

P2860

Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932